Muzerall D, Westheimer FH (1955) 1-Benzyldihydronicotinamide-A model for reduced DPN. 101:1059–1069.Įvans GW, Pouchnik DJ (1993) Composition and biological activity of chromium–pyridine carboxylate complexes. Shara M, Kincaid AE, Limpach AL, Sandstrom R, Barrett L, Norton N, Bramble JD, Yasmin T, Tran J, Chatterjee A, Bagchi M, Bagchi D (2007) Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex. Shara M, Yasmin T, Kincaid AE, Limpach AL, Bartz J, Brenneman KA, Chatterjee A, Bagchi M, Stohs SJ, Bagchi DJ (2005) Safety and toxicological evaluation of a novel niacin-bound chromium(III) complex. 97:335–346.īagchi D, Stohs SJ, Downs BW, Bagchi M, Preuss HG (2002) Cytotoxicity and oxidative mechanisms of different forms of chromium. 9:1643–1648.īagchi D, Bagchi M, Balmoori J, Ye X, Stohs SJ (1997) Comparative induction of oxidative stress in cultured J774A.1 macrophage cells by chromium picolinate and chromium nicotinate. Stearns DM, Wise JP Sr., Patierno SR, Wetterhahn KE (1995) Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. Olin KL, Stearns DM, Armstrong WH, Keen CL (1994) Comparative retention/absorption of chromium ( 51Cr) from 51Cr chloride, 51Cr nicotinate and 51Cr picolinate in a rat model. 66:119–130.Īnderson RA, Bryden NA, Polansky MM, Gautschi KJ (1996) Dietary chromium effects on tissue chromium concentrations and chromium absorption in rats. 72:79–88.īroadhurst CL, Schmidt WF, Reeves JB III, Polansky MM, Gautschi K, Anderson RA (1997) Characterization and structure by NMR and FTIR spectroscopy, and molecular modeling of chromium(III) picolinate and nicotinate complexes utilized for nutritional supplementation.

Kingry KF, Royer AC, Vincent JB (1998) Nuclear magnetic resonance studies of chromium(III) pyridine carboxylate complexes. Green CA, Bianchini RJ, Legg JI (1984) Characterization of a stable chromium(III)–nicotinic acid complex by deuteron NMR. Polyhedron 20:1–26.īroderick WE, Legg JI (1985) Synthesis of the first stable nitrogen coordinated nicotinic acid chromium(III) complexes: cis- and trans-H. Vincent JB (2001) The bioinorganic chemistry of chromium. Simonoff M, Shapcott D, Alameddine S, Sutter-Dub MT, Simonoff G (1992) The isolation of glucose tolerance factors from brewer’s yeast and their relationship to chromium. Hwang DL, Lev-Ran A, Papoian T, Beech WK (1987) Insulin-like activity of chromium-binding fractions from brewer’s yeast. Holdsworth ES, Kaufman DV, Neville E (1991) A fraction derived from brewer’s yeast inhibits cholesterol synthesis by rat liver preparations in vitro. Holdsworth ES, Neville E (1990) Effects of extracts of high- and low-chromium brewer’s yeast on metabolism of glucose by hepatocytes from rats fed on high- or low-Cr diets. Held DD, Gonzalez-Vergara E, Goff HM (1984) Isolation of a non-chromium insulin-enhancing factor from brewer’s yeast. 33:2275–2280.ĭavies DM, Holdsworth ES, Sherriff JL (1985) The isolation of glucose tolerance factors from brewer’s yeast and their relationship to chromium. Mertz W, Toepfer EW, Roginski EE, Polansky MM (1974) Present knowledge of the role of chromium. 25:162–166.Īnderson RA, Mertz W (1977) Glucose tolerance factor: An essential dietary agent. Toepfer EW, Mertz W, Polansky MM, Roginski WW, Wolf WR (1977) Preparation of chromium-containing material of glucose tolerance factor activity from brewer’s yeast extracts and by synthesis. Stallings D, Vincent JB (2006) Chromium: A case study on how not to perform nutraceutical research. Schwarz K, Mertz W (1959) Chromium(III) and the glucose tolerance factor. Schwarz K, Mertz W (1957) A glucose tolerance factor and its differentiation from factor 3. Mertz W, Schwarz K (1955) Impaired intravenous glucose tolerance as an early sign of dietary necrotic liver degeneration.

Cobra rad speed one length iron set